ABOUT US

Aprimus Diagnostics sells a Test Kit that includes: the disposable smart meter and 20 immunochromatographic tests calibrated for the specific lot of chemistry. For patients, a single test will be administered in a doctor's office.

The first product Aprimus will be bringing to market will be the D-Dimer test. D-Dimer is a protein fragment found within the bloodstream after a blood clot is broken down. The Aprimus D-Dimer test will identify and quantify the coagulation status of patients with deep vein thrombosis (DVT) and pulmonary embolism (PE). Other product tests used for diagnosing other critical disease biomarkers will follow.

An Aprimus D-Dimer test is similar to other venipuncture or fingerstick techniques, where a blood sample is collected and gets dropped into the sample well of the cassette tray, followed by a few drops of buffer solution. The cassette tray slides inside the smart meter where the Aprimus proprietary quantitative lateral flow assay (qLFA) test is performed.

The turnaround time for results is typically 10-15 minutes.

D-Dimer will be available only thru a professional medical healthcare provider or office. Aprimus will be working on future self-test products. 

Aprimus expects test kits to be in the public markets by later 2025.

Not at this time. Aprimus has recently received a Notice of Allowance from the US Patent office for the smart meter. Aprimus Diagnostics will be working thru the regulatory processes for CE and 510k thru the remainder of 2024 and into 2025. 

The Aprimus product design is unique and is designed to provide the most accurate and precise quantitative reading for disease biomarkers. The access to the numerical results can help professionals make frequent monitoring easier - saving patients valuable time scheduling appointments and avoiding extra costs for intermittent medications or being hospitalized. Most important, Aprimus can help people live longer through better healthcare and advanced diagnostics!